ATE486870T1 - Jnk inhibitoren - Google Patents

Jnk inhibitoren

Info

Publication number
ATE486870T1
ATE486870T1 AT06254089T AT06254089T ATE486870T1 AT E486870 T1 ATE486870 T1 AT E486870T1 AT 06254089 T AT06254089 T AT 06254089T AT 06254089 T AT06254089 T AT 06254089T AT E486870 T1 ATE486870 T1 AT E486870T1
Authority
AT
Austria
Prior art keywords
jnk inhibitors
present
compounds
apoptosis
jun
Prior art date
Application number
AT06254089T
Other languages
English (en)
Inventor
Afzal Khan
Darren P Medland
Gurpreet S Bhatia
Original Assignee
Eisai R&D Man Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Man Co Ltd filed Critical Eisai R&D Man Co Ltd
Application granted granted Critical
Publication of ATE486870T1 publication Critical patent/ATE486870T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Psychiatry (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Structures Of Non-Positive Displacement Pumps (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT06254089T 2005-08-05 2006-08-03 Jnk inhibitoren ATE486870T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0516156.7A GB0516156D0 (en) 2005-08-05 2005-08-05 JNK inhibitors

Publications (1)

Publication Number Publication Date
ATE486870T1 true ATE486870T1 (de) 2010-11-15

Family

ID=34984169

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06254089T ATE486870T1 (de) 2005-08-05 2006-08-03 Jnk inhibitoren

Country Status (6)

Country Link
US (2) US7645769B2 (de)
EP (1) EP1749829B1 (de)
AT (1) ATE486870T1 (de)
DE (1) DE602006017930D1 (de)
ES (1) ES2355738T3 (de)
GB (1) GB0516156D0 (de)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20040111445A (ko) * 2002-03-28 2004-12-31 에자이 가부시키가이샤 신경퇴행성 질환 치료용 ｃ─Ｊｕｎ Ｎ─말단 키나아제억제제로서의 ７─아자인돌
GB0305142D0 (en) * 2003-03-06 2003-04-09 Eisai London Res Lab Ltd Synthesis
WO2004101565A2 (en) * 2003-05-16 2004-11-25 Eisai Co., Ltd. Jnk inhibitors
PL1696920T3 (pl) 2003-12-19 2015-03-31 Plexxikon Inc Związki i sposoby opracowywania modulatorów Ret
GB0405055D0 (en) * 2004-03-05 2004-04-07 Eisai London Res Lab Ltd JNK inhibitors
US7498342B2 (en) 2004-06-17 2009-03-03 Plexxikon, Inc. Compounds modulating c-kit activity
CA2608733A1 (en) 2005-05-17 2007-02-01 Plexxikon, Inc. Pyrrol (2,3-b) pyridine derivatives protein kinase inhibitors
DK2395004T3 (en) 2005-06-22 2016-03-21 Plexxikon Inc Pyrrolo [2,3-b] pyridine derivatives as protein kinase inhibitors
GB0516156D0 (en) * 2005-08-05 2005-09-14 Eisai London Res Lab Ltd JNK inhibitors
US7405302B2 (en) * 2005-10-11 2008-07-29 Amira Pharmaceuticals, Inc. 5-lipoxygenase-activating protein (FLAP) inhibitors
US7977359B2 (en) 2005-11-04 2011-07-12 Amira Pharmaceuticals, Inc. 5-lipdxygenase-activating protein (FLAP) inhibitors
GB2431927B (en) 2005-11-04 2010-03-17 Amira Pharmaceuticals Inc 5-Lipoxygenase-activating protein (FLAP) inhibitors
US8399666B2 (en) 2005-11-04 2013-03-19 Panmira Pharmaceuticals, Llc 5-lipoxygenase-activating protein (FLAP) inhibitors
AU2007254179B2 (en) * 2006-05-18 2013-03-21 Pharmacyclics Llc Intracellular kinase inhibitors
WO2008063888A2 (en) 2006-11-22 2008-05-29 Plexxikon, Inc. Compounds modulating c-fms and/or c-kit activity and uses therefor
WO2008079909A1 (en) * 2006-12-21 2008-07-03 Plexxikon, Inc. Pyrrolo [2,3-b] pyridines as kinase modulators
WO2008080015A2 (en) 2006-12-21 2008-07-03 Plexxikon, Inc. Compounds and methods for kinase modulation, and indications therefor
PE20081581A1 (es) 2006-12-21 2008-11-12 Plexxikon Inc COMPUESTOS PIRROLO[2,3-b]PIRIDINAS COMO MODULADORES DE QUINASA
GB0702265D0 (en) * 2007-02-06 2007-03-14 Eisai London Res Lab Ltd 7-Azaindole derivatives
US20100190777A1 (en) 2007-07-17 2010-07-29 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
TW200920369A (en) 2007-10-26 2009-05-16 Amira Pharmaceuticals Inc 5-lipoxygenase activating protein (flap) inhibitor
UA101004C2 (en) * 2007-12-13 2013-02-25 Теракос, Инк. Derivatives of benzylphenylcyclohexane and use thereof
CN102137858B (zh) 2008-05-23 2014-07-23 潘米拉制药有限责任公司 5-脂氧合酶-活化蛋白抑制剂
GB0814364D0 (en) * 2008-08-05 2008-09-10 Eisai London Res Lab Ltd Diazaindole derivatives and their use in the inhibition of c-Jun N-terminal kinase
DE102008038221A1 (de) 2008-08-18 2010-02-25 Merck Patent Gmbh 7-Azaindolderivate
PT2324002T (pt) * 2008-08-22 2016-11-09 Theracos Sub Llc Processos para a preparação de inibidores de sglt2
US8546431B2 (en) 2008-10-01 2013-10-01 Panmira Pharmaceuticals, Llc 5-lipoxygenase-activating protein (FLAP) inhibitors
FR2938538B1 (fr) * 2008-11-17 2011-08-05 Univ Nice Sophia Antipolis Procede de preparation d'acides et d'esters boroniques en presence de magnesium metallique
HUE027598T2 (en) 2009-04-03 2016-10-28 Hoffmann La Roche Propane-1-sulfonic acid {3- [5- (4-chlorophenyl) -1H-pyrrolo [2,3-B] pyridine-3-carbonyl] -2,4-difluorophenyl} amide compositions and their uses
DK2442809T3 (en) 2009-06-17 2016-12-19 Vertex Pharma Inhibitors of the replication of influenza virus
US8329724B2 (en) 2009-08-03 2012-12-11 Hoffmann-La Roche Inc. Process for the manufacture of pharmaceutically active compounds
ES2633317T3 (es) 2009-11-06 2017-09-20 Plexxikon, Inc. Compuestos y métodos para la modulación de quinasas, e indicaciones para ello
WO2011153712A1 (en) 2010-06-12 2011-12-15 Theracos, Inc. Crystalline form of benzylbenzene sglt2 inhibitor
AU2011343642A1 (en) 2010-12-16 2013-05-02 Vertex Pharmaceuticals Incorporated Inhibitors of influenza viruses replication
MA34948B1 (fr) 2011-02-07 2014-03-01 Plexxikon Inc Composes et procedes de modulation de kinase, et leurs indications
TWI558702B (zh) 2011-02-21 2016-11-21 普雷辛肯公司 醫藥活性物質的固態形式
UA118010C2 (uk) 2011-08-01 2018-11-12 Вертекс Фармасьютікалз Інкорпорейтед Інгібітори реплікації вірусів грипу
WO2013152476A1 (en) 2012-04-10 2013-10-17 Theracos, Inc. Process for the preparation of benzylbenzene sglt2 inhibitors
US9150570B2 (en) 2012-05-31 2015-10-06 Plexxikon Inc. Synthesis of heterocyclic compounds
EP2981264B1 (de) * 2013-04-02 2018-04-25 F.Hoffmann-La Roche Ag Brutons tyrosin kinase inhibitoren
CN105611920B (zh) 2013-10-12 2021-07-16 泰拉科斯萨普有限责任公司 羟基-二苯甲烷衍生物的制备
EP3066090A1 (de) * 2013-11-08 2016-09-14 iTeos Therapeutics Neuartige 4-(indol-3-yl)-pyrazol-derivate, pharmazeutische zusammensetzungen und verfahren zur verwendung
RS57541B1 (sr) 2013-11-13 2018-10-31 Vertex Pharma Postupci za pripremu inhibitora replikacije virusa gripa
EP3068776B1 (de) 2013-11-13 2019-05-29 Vertex Pharmaceuticals Incorporated Hemmer der influenzavirenreplikation
JP6704416B2 (ja) 2015-05-13 2020-06-03 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ インフルエンザウイルスの複製の阻害剤を調製する方法
MA42422A (fr) 2015-05-13 2018-05-23 Vertex Pharma Inhibiteurs de la réplication des virus de la grippe
CN107434807A (zh) * 2017-09-20 2017-12-05 上海泓博智源医药股份有限公司 一种5‑羟基‑7‑氮杂吲哚的制备方法
CN111099625B (zh) * 2018-10-25 2021-10-01 中国石油化工股份有限公司 分子筛scm-24、其合成方法及其用途
CN111171019A (zh) * 2018-11-13 2020-05-19 上海轶诺药业有限公司 一类五元并六元杂环化合物及其作为蛋白受体激酶抑制剂的用途

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4719218A (en) 1985-12-12 1988-01-12 Smithkline Beckman Corporation Pyrrolo[1,2-a]imidazole and pyrrolo[1,2-a]pyridine derivatives and their use as 5-lipoxygenase pathway inhibitor
GB9026926D0 (en) 1990-12-12 1991-01-30 Smith Kline French Lab Novel process
ZA919797B (en) 1990-12-13 1992-10-28 Smithkline Beecham Corp Bicyclo-5,6-dihydro-7h-pyrrolo-1,20-imidazol-7-ols and 7-ones
SE9100920D0 (sv) 1991-03-27 1991-03-27 Astra Ab New active compounds
JP3119758B2 (ja) 1993-02-24 2000-12-25 日清製粉株式会社 ７−アザインドール誘導体及びこれを有効成分とする抗潰瘍薬
GB9315017D0 (en) 1993-07-20 1993-09-01 Glaxo Lab Sa Chemical compounds
FR2732969B1 (fr) 1995-04-14 1997-05-16 Adir Nouveaux composes pyridiniques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
WO1998047899A1 (en) 1997-04-24 1998-10-29 Ortho-Mcneil Corporation, Inc. Substituted pyrrolopyridines useful in the treatment of inflammatory diseases
GB9721437D0 (en) 1997-10-10 1997-12-10 Glaxo Group Ltd Heteroaromatic compounds and their use in medicine
CA2306870A1 (en) 1997-10-20 1999-04-29 David Michael Goldstein Bicyclic kinase inhibitors
WO1999051233A1 (en) 1998-04-02 1999-10-14 Merck & Co., Inc. Antagonists of gonadotropin releasing hormone
JP2002528543A (ja) 1998-10-30 2002-09-03 メルク エンド カムパニー インコーポレーテッド トロンビン阻害剤
AU752186B2 (en) 1998-10-30 2002-09-12 Merck & Co., Inc. Thrombin inhibitors
CN1136217C (zh) 1998-12-17 2004-01-28 霍夫曼-拉罗奇有限公司 作为jnk蛋白质激酶抑制剂的4-芳基羟吲哚
WO2000035921A1 (en) 1998-12-17 2000-06-22 F. Hoffmann-La Roche Ag 4,5-pyrazinoxindoles as protein kinase inhibitors
US6265403B1 (en) 1999-01-20 2001-07-24 Merck & Co., Inc. Angiogenesis inhibitors
GB9904933D0 (en) 1999-03-04 1999-04-28 Glaxo Group Ltd Compounds
EP1175399B1 (de) 1999-04-23 2009-03-11 Vertex Pharmaceuticals Incorporated Inhibitoren von c-jun n-terminal kinasen (jnk)
US6239132B1 (en) 1999-04-23 2001-05-29 Merck & Co., Inc. Thrombin inhibitors
AU780306B2 (en) 1999-08-19 2005-03-17 Signal Pharmaceuticals, Inc. Pyrazoloanthrone and derivatives thereof as JNK inhibitors and their compositions
US6642375B2 (en) 1999-12-07 2003-11-04 Fuji Photo Film Co., Ltd. Fluorescent substances
EP1990343B1 (de) 1999-12-24 2012-04-04 Aventis Pharma Limited Azaindole
JP2003525874A (ja) 2000-01-06 2003-09-02 メルク フロスト カナダ アンド カンパニー プロテアーゼ阻害剤としての新規化合物および組成物
US6897231B2 (en) * 2000-07-31 2005-05-24 Signal Pharmaceuticals, Inc. Indazole derivatives as JNK inhibitors and compositions and methods related thereto
PE20020506A1 (es) 2000-08-22 2002-07-09 Glaxo Group Ltd Derivados de pirazol fusionados como inhibidores de la proteina cinasa
GB0108770D0 (en) 2001-04-06 2001-05-30 Eisai London Res Lab Ltd Inhibitors
WO2003028724A1 (en) 2001-10-04 2003-04-10 Smithkline Beecham Corporation Chk1 kinase inhibitors
KR20040111445A (ko) 2002-03-28 2004-12-31 에자이 가부시키가이샤 신경퇴행성 질환 치료용 ｃ─Ｊｕｎ Ｎ─말단 키나아제억제제로서의 ７─아자인돌
KR20050013534A (ko) 2002-03-28 2005-02-04 에자이 가부시키가이샤 ｃ─Ｊｕｎ Ｎ─말단 키나아제 억제용 아자인돌
SE0202463D0 (sv) 2002-08-14 2002-08-14 Astrazeneca Ab Novel compounds
GB0305142D0 (en) 2003-03-06 2003-04-09 Eisai London Res Lab Ltd Synthesis
EP1599475A2 (de) 2003-03-06 2005-11-30 Eisai Co., Ltd. Jnk-hemmer
WO2004101565A2 (en) 2003-05-16 2004-11-25 Eisai Co., Ltd. Jnk inhibitors
WO2005085224A1 (ja) * 2004-03-04 2005-09-15 National Institute Of Advanced Industrial Science And Technology 環状カーボネート類の製造方法
GB0405055D0 (en) 2004-03-05 2004-04-07 Eisai London Res Lab Ltd JNK inhibitors
GB0516156D0 (en) * 2005-08-05 2005-09-14 Eisai London Res Lab Ltd JNK inhibitors

Also Published As

Publication number Publication date
EP1749829A1 (de) 2007-02-07
EP1749829B1 (de) 2010-11-03
ES2355738T3 (es) 2011-03-30
GB0516156D0 (en) 2005-09-14
US20100035878A1 (en) 2010-02-11
DE602006017930D1 (de) 2010-12-16
US20070072896A1 (en) 2007-03-29
US7645769B2 (en) 2010-01-12

Similar Documents

Publication Publication Date Title
DE602006017930D1 (de) JNK Inhibitoren
GB0405055D0 (en) JNK inhibitors
WO2004078756A3 (en) Jnk inhibitors
DE60204553D1 (de) Jun kinase inhibitoren
WO2004101565A3 (en) Jnk inhibitors
DE60316542D1 (de) 7-azaindole als inhibitoren c-jun n-terminaler kinasen zur behandlung neurodegenerativer störungen
ATE456571T1 (de) Proteasom-hemmer und verwendungsverfahren dafür
ATE530540T1 (de) Pyrimidonverbindungen als gsk-3-inhibitoren
DE60331219D1 (de) Azaindole als hemmstoffe von c-jun n-terminalen kinasen
PL1660507T5 (pl) Inhibitory proteazomu oraz sposoby ich stosowania
TW200714604A (en) Substituted heterocycles and the uses thereof
NO20072558L (no) Mitotiske kineseinhibitorer og fremgangsmater for anvendelse derav
EA200900798A1 (ru) Производные индол-4-илпиримидинил-2-иламина и их применение в качестве ингибиторов циклинзависимой киназы
EA200970542A1 (ru) ИНГИБИТОРЫ ДЕЙСТВИЯ Akt
EA201170531A1 (ru) Соединения на основе пиридина и пиримидина в качестве ингибиторов сигнального пути wnt для лечения рака
NO20075074L (no) Kinazolinon T-type-kalsiumkanalantagonister
ATE497496T1 (de) 2,4-pyridimediamon-derivate als hemmer von jak- kinasen zur behandlung von autoimmunerkrankungen
ATE423087T1 (de) Proteasome inhibitoren und deren verwendung
TW200505904A (en) Heterocyclyl-3-sulfonylindazoles as 5-hydroxytryptamine-6 ligands
ATE542800T1 (de) Kinasehemmer und ihre anwendungsverfahren
ATE502935T1 (de) C-met-proteinkinasehemmer
NO20055563L (no) Midler for behandlingen av lavere abdominale lidelser
TW200740808A (en) Inhibiteurs de proteines kinases
PT1904048E (pt) Inibidores de glepp-1 no tratamento de distúrbios autoimunes e/ou inflamatórios
TW200603791A (en) Compounds and compositions as cathepsin S inhibitors

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties